ViGeneron and Daiichi Sankyo Expand Collaboration on Next-Generation Gene Therapy for Common Ophthalmic Diseases

Recently, ViGeneron, dedicated to developing the next generation of gene therapies, announced a follow-up R&D collaboration with Daiichi Sankyo Company Limited. The collaboration will utilize its innovative engineered recombinant adeno-associated virus vectors (vgAAVs) to target an undisclosed site for the treatment of a common ophthalmic disease.

ViGeneron and Daiichi Sankyo's collaboration on this research and development project began in early 2021. This subsequent collaboration allows both parties to construct and validate vgAAV-based candidate therapies until the completion of in vivo animal studies. ViGeneron’s unique and stringent in vivo screening technology involves intravenously administering an AAV2-based peptide-display library in mouse models, followed by isolating vector DNA from target cells after 24 hours. Using this technology, ViGeneron discovered and characterized two novel vgAAV vectors called vgAAV.GL and vgAAV.NN. These innovative vgAAV vectors mediated extensive and high-level retinal transduction following intravitreal injection across a wide range of preclinical models and effectively transduced photoreceptor cells in human retinal explant cultures.

Note: The original text has been abridged.

▽Follow 【WuXi AppTecGermany】WeChat Official Account